Immuto Scientific’s Post

Are you looking for an easy way to screen your compounds against an inflammation gut model? Check out our webinar!

How does one take the first step into the antibody industry? In this episode of The Chain, Tariq Ghayur talks with Janine Schuurman, the new president of The Antibody Society, about her inspiration to get into antibody engineering, her impressive career at Genmab, her advice for achieving a productive work environment, and her current work. Dr. Schuurman also shares insights on staying innovative, how to deal with the challenges of the industry, and why young scientists in the industry should not be afraid to fail. Listen now https://lnkd.in/eWy2wYB3 #antibodydiscovery #antibodytherapeutics #antibody

We have just published our second quarter 2024 Business Update and financial results. With effective execution and on track towards our 2024 milestones, we continue making significant progress across our three-pronged business model focusing on Targets, Pipeline, and Responders.   Since our last quarterly release, several partnership discussions are ongoing as we further advance our multi-partner approach. Moreover positive Phase 2 immune data on our lead asset, EVX-01, was presented at ASCO and 67% Objective Response Rate (ORR) from Phase 1 published in leading medical journal . As we prepare for the upcoming Phase 2 one-year clinical data readout at ESMO Congress 2024, we remain focused on delivering solid progress in this program.   On the technology front, our AI-Immunology™ platform continues to strengthen, showcased by the improved performance of key components presented at a recent computational biology conference. This is also supported by the encouraging positive feedback by the World Intellectual Property Organization's on our patent application for an AI-Immunology™ driven novel cancer target identification method.   We remain dedicated to advancing our pipeline and business development discussions. With our current cash position, we remain funded into February 2025.   You can find the full Q2 2024 Business Update here: https://lnkd.in/dfYzpWAE   #Evaxion #Biotech #AIImmunology #CancerResearch #Innovation

🌉 From San Francisco, JP Morgan Healthcare Conference Day 2 Highlights in Genomics and Diagnostics 🧬 1️⃣ Thermo Fisher Scientific: CEO Marc Casper spotlighted the $3.1 billion acquisition of Olink and growth projections for 2024, along with their high-demand Orbitrap Astral mass spectrometer. 2️⃣ Illumina: CEO Jacob Thaysen discussed the future of Grail and the widespread adoption of the NovaSeq X system, with a shift in market focus from sequencing costs to end-to-end workflow efficiency. 3️⃣ Oxford Nanopore Technologies: CEO Gordon Sanghera emphasized their leap towards clinical applications by 2026, fueled by improved Q20+ sequencing accuracy. 4️⃣ Natera: CEO Steve Chapman outlined their financial growth, driven by the Signatera test and improvements in test reimbursements and billing operations. 5️⃣ Agilent Technologies: CEO Mike McMullen projected a recovery year in 2024, with a focus on cancer testing and therapy development. #JPMHC24 #Genomics #Diagnostics #HealthcareInnovation #Biotech

Join our 𝐅𝐑𝐄𝐄 webinar delving into the shift towards animal-free models with experts Aline Miller, Darius Widera, Dominik Egger, and Tamara Zietek! ✨ 📆 Wednesday 17th April 2024 🕓 14:00 BST | 09:00 EDT 🖥️ Register here: https://hubs.la/Q02sxk800 𝐃𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧 𝐭𝐨𝐩𝐢𝐜𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: ✔️ Innovations in synthetic hydrogel scaffolds and growth factors ✔️ Exploring the ethical and scientific benefits of animal-free 3D cell culture models ✔️ Applications in regenerative medicine and drug discovery #OGCell #3DCellCulture #DrugDiscovery

We're at SLAS! See our first poster presentation at 2pm EST and speak to one of the lead authors Dr Sian Humphreys. At 2pm EST today (Track: Cellular Technologies, poster session B) we're presenting our first SLAS poster titled "Differentiation of multiple iPSC lines to different cell types to enable cohort analysis in neurodegeneration: challenges and learnings". Tomorrow at 10am EST, we'll also be joined by our friends from Axion BioSystems at our booth (#224) to discuss iPSC technology, MEA, QC and phenotyping of advanced in vitro models. #iPSCs #SLAS #biotech #StemCells #DrugDiscovery

Join our 𝐅𝐑𝐄𝐄 webinar delving into the shift towards animal-free models with experts Aline Miller, Darius Widera, Dominik Egger, and Tamara Zietek! ✨ 📆 Wednesday 17th April 2024 🕓 14:00 BST | 09:00 EDT 🖥️ Register here: https://hubs.la/Q02sxhyZ0 𝐃𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧 𝐭𝐨𝐩𝐢𝐜𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: ✔️ Innovations in synthetic hydrogel scaffolds and growth factors ✔️ Exploring the ethical and scientific benefits of animal-free 3D cell culture models ✔️ Applications in regenerative medicine and drug discovery #OGCell #3DCellCulture #DrugDiscovery

Join this free #webinar where we will discuss how to move towards animal-free #science! #3dcellculture #animalfreeresearch #nonanimalmethods #organoids #NAMs #MPS #research

🔉 Promising news in cell therapy! 🤝 PhenomeX, born from Berkeley Lights' acquisition of IsoPlexis, is now set to join forces with Bruker. 🔬With over 400 instruments, PhenomeX specializes in single-cell research, unlocking insights in functional cell biology. 👉 Their advanced platforms will integrate with Bruker's solutions, propelling spatial biology initiatives. 📈 It's a strategic move that promises significant strides in antibody therapeutics and cell therapy. 👀 The $57.8 million all-stock deal is on track to close by year-end, and there are great things to come - this is one to keep an eye on. Read more from the link below Metric Search #celltherapy #cellandgenetherapy #genetherapy #biotechnology #therapeutics #antibodytherapeutics #antibody https://lnkd.in/etuSRZhM

Elevate Your Antibody Research with AccuScience's Advanced Solutions! 🔬 Discover the potential of our premium product offerings: Bio-Rad Laboratories 🌌 Pioneer Antibody Discovery Platform Dive into an extensive Fab antibody library, featuring a staggering 2.25 x 10¹¹ unique antibodies. Simplify your discovery process with SpyDisplay technology. Achieve top-notch developability with minimized post-translational modifications. ✨ Illuminate Your Results with StarBright Dyes Embrace unmatched brightness, precision, and compatibility in flow cytometry. Harness dyes optimized for UV, violet, blue, yellow/green, and red lasers. Trust in consistent staining across all immunophenotyping targets. At Accuscience, we're committed to fueling your research endeavors. Our team is here to assist, guiding you to find the perfect solution tailored to your needs. #AccuScienceAdvantage #AntibodyResearch #StarBrightDyes #PioneerPlatform #FlowCytometryTech #NextGenResearchTools #PrecisionInResearch